San Francisco, United States
Siren Biotechnology, founded in 2020, is a pioneering company situated in the expansive field of Biotechnology. Headquartered in the United States, the company has taken a bold step in the fight against cancer with its innovative approach: Universal AAV Immuno-Gene Therapy.
The company uniquely integrates two groundbreaking therapeutic technologies: AAV gene therapy and cytokine immunotherapy. This combination creates a novel modality designed to overcome conventional challenges in cancer treatment. Through its initiative, Siren Biotechnology aims to redefine the destruction of tumor cells while also enhancing anti-tumor immunity.
Recently, the company received grant investment on 04 June 2024, backed by the notable life science company, MilliporeSigma. This endorsement reflects the promising potential of their technology in transforming the therapeutic landscape.
With its slogan, "Universal AAV immuno-gene therapy: Sounding the alarm against cancer," Siren Biotechnology epitomizes a courageous stride towards advanced cancer treatments, appealing significantly to investors keen on cutting-edge biotechnology solutions.
